DK1139743T3 - Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger - Google Patents
Exo-S-mecamylaminformulering og anvendelse heraf i behandlingerInfo
- Publication number
- DK1139743T3 DK1139743T3 DK99967401T DK99967401T DK1139743T3 DK 1139743 T3 DK1139743 T3 DK 1139743T3 DK 99967401 T DK99967401 T DK 99967401T DK 99967401 T DK99967401 T DK 99967401T DK 1139743 T3 DK1139743 T3 DK 1139743T3
- Authority
- DK
- Denmark
- Prior art keywords
- exo
- mecamylamine
- pharmaceutically acceptable
- disorder
- amount
- Prior art date
Links
- 229960002525 mecamylamine Drugs 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000005586 smoking cessation Effects 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010020802 Hypertensive crisis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 230000000923 atherogenic effect Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000008559 autonomic dysreflexia Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003368 psychostimulant agent Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- 230000003033 spasmogenic effect Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11253498P | 1998-12-16 | 1998-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1139743T3 true DK1139743T3 (da) | 2006-07-31 |
Family
ID=22344414
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99967401T DK1139743T3 (da) | 1998-12-16 | 1999-12-16 | Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger |
| DK05024899T DK1634498T3 (da) | 1998-12-16 | 1999-12-16 | Exo-S-mecamylamine formulation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05024899T DK1634498T3 (da) | 1998-12-16 | 1999-12-16 | Exo-S-mecamylamine formulation |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20020016370A1 (enExample) |
| EP (3) | EP1139743B1 (enExample) |
| JP (5) | JP2002532393A (enExample) |
| AT (2) | ATE320711T1 (enExample) |
| AU (2) | AU2368200A (enExample) |
| CA (2) | CA2393437C (enExample) |
| CY (1) | CY1108577T1 (enExample) |
| DE (2) | DE69939498D1 (enExample) |
| DK (2) | DK1139743T3 (enExample) |
| ES (2) | ES2313187T3 (enExample) |
| PT (2) | PT1139743E (enExample) |
| WO (2) | WO2000035280A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| EP1578422B1 (en) | 2002-12-20 | 2007-04-11 | NicoNovum AB | A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material |
| US20070224284A1 (en) * | 2004-03-12 | 2007-09-27 | John Devane | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
| NZ542260A (en) * | 2003-03-14 | 2009-03-31 | Agi Therapeutics Res Ltd | Treatment of intestinal conditions with mecamylamine |
| DE10318714B4 (de) * | 2003-04-25 | 2006-03-23 | Hf Arzneimittelforschung Gmbh | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| JP2009519962A (ja) * | 2005-12-19 | 2009-05-21 | コメンティス，インコーポレーテッド | 眼投与用局所メカミルアミン製剤およびその使用 |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
| JP2010505960A (ja) * | 2006-10-09 | 2010-02-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | ニコチン禁断症状および／またはタバコ使用の軽減用組成物 |
| US20080243005A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242952A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liablity Corporation Of The State Of Delaware | Effective response protocols for health monitoring or the like |
| US20080319276A1 (en) * | 2007-03-30 | 2008-12-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242947A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Configuring software for effective health monitoring or the like |
| US20080242948A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
| US20090018407A1 (en) * | 2007-03-30 | 2009-01-15 | Searete Llc, A Limited Corporation Of The State Of Delaware | Computational user-health testing |
| US20090005653A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242949A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20090119154A1 (en) * | 2007-11-07 | 2009-05-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content |
| US20090005654A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242951A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
| EP1977746B8 (en) * | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
| WO2009143403A1 (en) * | 2008-05-23 | 2009-11-26 | Targacept, Inc. | Combination therapy for the management hypertension |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| CA2764927A1 (en) * | 2009-07-14 | 2011-01-20 | Targacept, Inc. | Exo-s-mecamylamine method, use, and compound for treatment |
| TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| RU2582339C2 (ru) * | 2010-05-27 | 2016-04-27 | Таргасепт, Инк. | Неконкурентные антагонисты никотиновых рецепторов |
| AT510837B1 (de) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| CA2824970C (en) | 2011-02-11 | 2016-05-03 | Batmark Limited | Inhaler component |
| US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| KR102671442B1 (ko) | 2011-09-06 | 2024-05-30 | 니코벤처스 트레이딩 리미티드 | 가열식 끽연 가능 물질 |
| MY164560A (en) | 2011-09-06 | 2018-01-15 | British American Tobacco Investments Ltd | Heating Smokeable Material |
| AT511344B1 (de) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| US8901177B2 (en) * | 2012-03-23 | 2014-12-02 | Targacept, Inc. | Method of treating bladder disorders |
| GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
| GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| GB2504075A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
| GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
| GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
| GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
| ES2886106T3 (es) * | 2014-08-22 | 2021-12-16 | Atacama Therapeutics Inc | Dexmecamilamina para su uso en el tratamiento de la hiperhidrosis |
| GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| GB201505597D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Article for use with apparatus for heating smokable material |
| GB201505595D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Cartridge for use with apparatus for heating smokeable material |
| GB201511361D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic vapour provision system |
| GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
| US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
| US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
| US11744964B2 (en) | 2016-04-27 | 2023-09-05 | Nicoventures Trading Limited | Electronic aerosol provision system and vaporizer therefor |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| AU2019279884B2 (en) | 2018-05-29 | 2025-01-30 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| JP2022507660A (ja) | 2018-11-16 | 2022-01-18 | モーニングサイド ベンチャー インベストメンツ リミテッド | 温度によって調節される経皮薬剤送達システム |
| GB202203728D0 (en) * | 2022-03-17 | 2022-05-04 | Univ Oxford Innovation Ltd | Treatments and methods for increasing dopamine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5039801A (en) * | 1985-12-20 | 1991-08-13 | The United States Of America As Represented By The Department Of Health & Human Services | Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines |
| US4749686A (en) * | 1986-12-04 | 1988-06-07 | New York Medical College | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases |
| EP0302595B1 (en) * | 1987-07-07 | 1994-02-02 | Beecham Group Plc | Pinacidil for treatment of pulmonary hypertension or right heart failure |
| US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
-
1999
- 1999-12-16 DE DE69939498T patent/DE69939498D1/de not_active Expired - Lifetime
- 1999-12-16 AU AU23682/00A patent/AU2368200A/en not_active Abandoned
- 1999-12-16 DK DK99967401T patent/DK1139743T3/da active
- 1999-12-16 JP JP2000587609A patent/JP2002532393A/ja not_active Withdrawn
- 1999-12-16 DK DK05024899T patent/DK1634498T3/da active
- 1999-12-16 PT PT99967401T patent/PT1139743E/pt unknown
- 1999-12-16 ES ES05024899T patent/ES2313187T3/es not_active Expired - Lifetime
- 1999-12-16 EP EP99967401A patent/EP1139743B1/en not_active Expired - Lifetime
- 1999-12-16 AT AT99967401T patent/ATE320711T1/de active
- 1999-12-16 WO PCT/US1999/030137 patent/WO2000035280A1/en not_active Ceased
- 1999-12-16 CA CA002393437A patent/CA2393437C/en not_active Expired - Fee Related
- 1999-12-16 DE DE69930552T patent/DE69930552T2/de not_active Expired - Lifetime
- 1999-12-16 CA CA002393442A patent/CA2393442A1/en not_active Abandoned
- 1999-12-16 WO PCT/US1999/030153 patent/WO2000035279A1/en not_active Ceased
- 1999-12-16 JP JP2000587608A patent/JP2002532392A/ja active Pending
- 1999-12-16 EP EP99967396A patent/EP1139744A4/en not_active Withdrawn
- 1999-12-16 PT PT05024899T patent/PT1634498E/pt unknown
- 1999-12-16 EP EP05024899A patent/EP1634498B1/en not_active Expired - Lifetime
- 1999-12-16 AT AT05024899T patent/ATE406797T1/de active
- 1999-12-16 AU AU23686/00A patent/AU2368600A/en not_active Abandoned
- 1999-12-16 ES ES99967401T patent/ES2260959T3/es not_active Expired - Lifetime
-
2001
- 2001-06-15 US US09/882,934 patent/US20020016370A1/en not_active Abandoned
-
2008
- 2008-11-19 CY CY20081101333T patent/CY1108577T1/el unknown
-
2011
- 2011-03-14 JP JP2011055716A patent/JP2011126909A/ja not_active Withdrawn
-
2013
- 2013-12-13 JP JP2013258032A patent/JP2014051528A/ja active Pending
-
2016
- 2016-01-25 JP JP2016011658A patent/JP2016065108A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT1139743E (pt) | 2006-06-30 |
| EP1139744A4 (en) | 2003-01-02 |
| JP2016065108A (ja) | 2016-04-28 |
| CA2393437A1 (en) | 2000-06-22 |
| DE69930552D1 (de) | 2006-05-11 |
| US20020016370A1 (en) | 2002-02-07 |
| EP1139743A4 (en) | 2003-01-02 |
| EP1634498A3 (en) | 2006-03-29 |
| ATE406797T1 (de) | 2008-09-15 |
| EP1634498A2 (en) | 2006-03-15 |
| JP2011126909A (ja) | 2011-06-30 |
| ES2313187T3 (es) | 2009-03-01 |
| DE69930552T2 (de) | 2006-11-30 |
| DE69939498D1 (de) | 2008-10-16 |
| ES2260959T3 (es) | 2006-11-01 |
| CA2393437C (en) | 2009-12-15 |
| JP2014051528A (ja) | 2014-03-20 |
| WO2000035280A1 (en) | 2000-06-22 |
| JP2002532393A (ja) | 2002-10-02 |
| PT1634498E (pt) | 2008-10-28 |
| AU2368600A (en) | 2000-07-03 |
| EP1139743B1 (en) | 2006-03-22 |
| EP1634498B1 (en) | 2008-09-03 |
| JP2002532392A (ja) | 2002-10-02 |
| EP1139744A1 (en) | 2001-10-10 |
| CY1108577T1 (el) | 2014-04-09 |
| WO2000035279A1 (en) | 2000-06-22 |
| EP1139743A1 (en) | 2001-10-10 |
| AU2368200A (en) | 2000-07-03 |
| CA2393442A1 (en) | 2000-06-22 |
| DK1634498T3 (da) | 2008-12-15 |
| ATE320711T1 (de) | 2006-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1139743E (pt) | Formulacao de exo-s-mecamilamina e utilizacao em tratamento | |
| PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
| TW200607509A (en) | Use of optically pure (S,S) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome | |
| BR0206559A (pt) | Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto | |
| MX348062B (es) | Mutantes que degradan proteoglicanos para tratamiento del snc. | |
| ATE481970T1 (de) | Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum | |
| ATE253039T1 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
| NZ522326A (en) | Adenosine A2A receptor antagonists | |
| Summers et al. | THA—a review of the literature and its use in treatment of five overdose patients | |
| Woods et al. | Distribution and metabolism of cocaine in the dog and rabbit | |
| JP2002532392A5 (enExample) | ||
| ATE433959T1 (de) | Analoge von kokain | |
| BRPI0506881A (pt) | derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou distúrbio ou condição de um corpo de animal vivo | |
| ES2187646T3 (es) | Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes. | |
| Durant et al. | Comparison of the neuromuscular blocking properties of Org NC 45 and pancuronium in the rat, cat and rhesus monkey | |
| NO984564L (no) | FremgangsmÕte for behandling av hjertesvikt med endothelinantagonister | |
| DE69814089T2 (de) | Verwendung von einem draflazin analog zur schmerzbehandlung | |
| Selby | The Graeme Robertson memorial lecture, 1983. The long-term prognosis of Parkinson's disease | |
| Feinberg et al. | Methadone and schizophrenia. | |
| Carlson | Supersensitivity to apomorphine and stress two years after chronic methadone treatment | |
| RU2192275C2 (ru) | Способ лечения опийной наркомании | |
| Middleton Jr et al. | Immediate Hypersensitivity: II. Drugs in Clinical Use | |
| RU99125671A (ru) | Способ лечения психоэмоциональных нарушений у детей при бронхиальной астме | |
| Boddeke et al. | Abstracts of papers pharmacological meeting | |
| WO2003032895A3 (en) | Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer |